Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 8, 2005, Pages 1143-1148

  Enjoji, Munechika ^a   Nakashima, Manabu ^b   Yamaguchi, Koji ^a   Kotoh, Kazuhiro ^a   Nakamuta, Makoto ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Pancreatic cancer; RCAS1; Tumor marker

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; BILE DUCT CARCINOMA; DISEASE ACTIVITY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; REVIEW;

EID: 27744439823     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03840.x     Document Type: Review

References (45)

1. Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996; 77: 1501-9.
2. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nature Med. 1999; 5: 938-42.
3. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M. Isolation of estrogen-responsive genes with a CpG island library. Mol. Cell. Biol. 1998; 18: 442-9.
4. Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin. Cancer Res. 1998; 4: 1517-20.
5. Kaku T, Sonoda K, Kamura T et al. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin. Cancer Res. 1999; 5: 1449-53.
6. Sonoda K, Kaku T, Hirakawa T et al. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol. Oncol. 2000; 79: 424-9.
7. Sonoda K, Miyamoto S, Hirakawa T et al. Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br. J. Cancer 2003; 89: 546-51.
8. Kubokawa M, Nakashima M, Yao T et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int. J. Oncol. 2001; 19: 695-700.
9. Nakakubo Y, Hida Y, Miyamoto M et al. The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett. 2002; 177: 101-5.
10. Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M, Kaibara N. The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 2002; 5: 220-7.
11. Ikeguchi M, Ohoro S, Maeta Y et al. Protein and gene expression of tumor-associated antigen RCAS1 in esophageal squamous cell carcinoma. Oncol. Rep. 2003; 10: 1891-4.
12. Okada K, Nakashima M, Komura K et al. Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Mod. Pathol. 2003; 16: 679-85.
13. Leelawat K, Watanabe T, Nakashima M, Tujinda S, Suthipintawong C, Leardkamolkarn V. Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J. Clin. Pathol. 2003; 56: 764-8.
14. Nakamura Y, Yamazaki K, Oizumi S et al. Expression of RCAs1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci. 2004; 95: 260-5.
15. Iwasaki T, Nakashima M, Watanabe T et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int. J. Cancer 2000; 89: 488-93.
16. Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001; 92: 446-51.
17. Oizumi S, Yamazaki K, Nakashima M et al. RCAS1 expression: a potential prognostic marker for adenocarcinomas of the lung. Oncology 2002; 62: 333-9.
18. Takahashi H, Iizuka H, Nakashima M et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. J. Dermatol. Sci. 2001; 26: 140-4.
19. Enjoji M, Noguchi K, Watanabe H et al. A novel tumor marker RCAS1 in a case of extramammary Paget's disease. Clin. Exp. Dermatol. 2003; 28: 211-13.
20. Umeoka K, Sanno N, Oyama K et al. Immunohistochemical analysis of RCAS1 in human pituitary adenomas. Mod. Pathol. 2001; 14: 1232-6.
21. Takahashi S, Urano T, Tsuchiya F et al. EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. Int. J. Cancer 2003; 106: 310-15.
22. Ito Y, Yoshida H, Nakano K et al. Overexpression of human tumor-associated antigen, RCAS1 is significantly linked to dedifferentiation of thyroid carcinoma. Oncology 2003; 64: 83-9.
23. Suzuki T, Inoue S, Kawabata W et al. EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br. J. Cancer 2001; 85: 1731-7.
24. Rousseau J, Tetu B, Danielle C et al. RCAS1 is associated with ductal breast cancer progression. Biochem. Biophys. Res. Commun. 2002; 293: 1544-9.
25. Watanabe H, Enjoji M, Nakashima M et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J. Hepatol. 2003; 39: 559-63.
26. Enjoji M, Yamaguchi K, Nakashima M et al. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Liver Int. 2004; 24: 330-4.
27. Enjoji M, Yamaguchi K, Nakamuta M et al. Movement of a novel serum tumor marker, RCAS1, in patients with biliary diseases. Dig. Liver Dis. 2004; 36: 622-7.
28. Enjoji M, Nakamuta M, Yamaguchi K et al. RCAS1, a useful marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer. Dig. Dis. Sci. 2004; 49: 1654-6.
29. Noguchi K, Enjoji M, Nakamuta M et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett. 2001; 168: 197-202.
30. Aoki T, Inoue S, Imamura H et al. EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur. J. Cancer 2003; 39: 1552-61.
31. Ikeguchi M, Hirooka Y, Kaibara N. Gene and protein expression of RCAS1 in hepatocellular carcinoma. Anticancer Res. 2003; 23: 4967-72.
32. Ikeguchi M, Oi K, Hirooka Y, Kaibara N. CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur. J. Surg. Oncol. 2004; 30: 53-7.
33. Oshikiri T, Hida Y, Miyamoto M et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br. J. Cancer 2001; 85: 1922-7.
34. Suzuoki M, Hida Y, Miyamoto M et al. RCAS1 expression as a prognostic factor after curative surgery for extra-hepatic bile duct carcinoma. Ann. Surg. Oncol. 2002; 9: 388-93.
35. Enjoji M, Nakashima M, Nishi H et al. The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of the biliary tract. J. Hepatol. 2002; 36: 786-92.
36. Hiraoka K, Hida Y, Miyamoto M et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer 2002; 99: 418-23.
37. Akashi T, Oimomi H, Nishiyama K et al. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas 2003; 26: 49-55.
38. Enjoji M, Nakamuta M, Noguchi K et al. RCAS1 expression in immune-mediated liver diseases. J. Clin. Gastroenterol. 2002; 34: 286-7.
39. Abe Y, Ohshima K, Nakashima M et al. Expression of apoptosis-associated protein RCAS1 in macrophages of histiocytic necrotizing lymphadenitis. Int. J. Hematol. 2003; 77: 359-63.
40. Honda M, Enjoji M, Sakai H, Yamamoto I, Tsuneyosi M, Nawata H. Intrahepatic cholangiocarcinoma with rhabdoid transformation. J. Gastroenterol. Hapatol. 1996; 11: 771-4.
41. Enjoji M, Nakashima M, Honda M, Sakai H, Nawata H. Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma cells treated with 5-azacytidine. Hepatology 1997; 26: 288-94.
42. Enjoji M, Nakashima M, Nakamuta M, Nawata H. Transforming growth factor-α induces the differentiation of sarcomatoid cholangiocarcinoma cells. Jpn J. Cancer Res. 2000; 91: 223-30.
43. Enjoji M, Nakashima M, Sakai H, Nawata H. Integrins: utility as cell type- and stage-specific markers for hepatocellular carcinoma and cholangiocarcinoma. In Vitro Cell. Dev. Biol. Anim. 1998; 34: 25-7.
44. Enjoji M, Nakamuta M, Kotoh K, Iwamoto H, Nawata H. Self-regulation of type I collagen degradation by collagen-induced production of matrix metalloproteinase-1 on cholangiocarcinoma and hepatocellular carcinoma cells. In Vitro Cell. Dev. Biol. Anim. 2000; 36: 71-3.
45. Enjoji M, Kajiyama K, Sakai H, Tsuneyosi M, Nawata H. Sarcomatous and adenocarcinoma cell lines from the same nodule of cholangiocarcinoma. In Vitro Cell. Dev. Biol. Anim. 1997; 33: 681-3.